SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Tyrstrup Mia)
 

Sökning: WFRF:(Tyrstrup Mia) > Clinical course of ...

  • Tell, DavidLinköpings universitet,Linköping University,Institutionen för hälsa, medicin och vård,Medicinska fakulteten,Futurum, Reg Jonkoping Cty, Sweden (författare)

Clinical course of pharyngotonsillitis with group A streptococcus treated with different penicillin V strategies, divided in groups of Centor Score 3 and 4: a prospective study in primary care

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2022-11-11
  • Springer Science and Business Media LLC,2022

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/320536
  • https://gup.ub.gu.se/publication/320536URI
  • https://doi.org/10.1186/s12879-022-07830-4DOI
  • https://lup.lub.lu.se/record/cb74396a-85f1-4849-b150-dab3224726f5URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-190203URI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|Public Health Agency of Sweden; Region Jonkoping County
  • Background Sore throat is a common reason for prescribing antibiotics in primary care, and 10 days of treatment is recommended for patients with pharyngotonsillitis with group A streptococcus (GAS). Our group recently showed that penicillin V (PcV) four times daily for 5 days was non-inferior in clinical outcome to PcV three times daily for 10 days. This study compares duration, intensity of symptoms, and side effects in patients with a Centor Score (CS) of 3 or 4 respectively, after treatment with PcV for 5 or 10 days and evaluates whether all patients with pharyngotonsillitis with a CS of 3 or 4 should be treated for 5 days or if severity of symptoms or CS suggest a longer treatment period. Method Data on symptoms and recovery from patient diaries from 433 patients included in a RCT comparing PcV 800 mg x 4 for 5 days or PcV 1 g x 3 for 10 days was used. Patients six years and older with CS-3 or CS-4 and positive rapid antigen detection test for GAS-infection were grouped based on CS and randomized treatment. Comparisons for categorical variables were made with Pearson's chi-squared test or Fisher's exact test. Continuous variables were compared with the Mann-Whitney U test. Results Patients with CS-3 as well as patients with CS-4 who received PcV 800 mg x 4 for 5 days self-reported that they recovered earlier compared to patients with CS-3 or CS-4 who received treatment with PcV 1 g x 3 for 10 days. In addition, the throat pain as single symptom was relieved 1 day earlier in patients with CS-4 and 5 days of treatment compared to patients with CS-4 and 10 days of treatment. No differences in side effects between the groups were found. Conclusion Intense treatment with PcV four times a day for 5 days seems clinically beneficial and strengthens the suggestion that the 4-dose regimen with 800 mg PcV for 5 days may be the future treatment strategy for GAS positive pharyngotonsillitis irrespectively of CS-3 or CS-4. Trail registration ClinicalTrials.gov ID: NCT02712307 (3 April 2016).

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Tyrstrup, MiaLund University,Lunds universitet,Allmänmedicin och samhällsmedicin,Forskargrupper vid Lunds universitet,Family Medicine and Community Medicine,Lund University Research Groups,Lund Univ, Sweden(Swepub:lu)med-mty (författare)
  • Edlund, C.Public Health Agency of Sweden (författare)
  • Rystedt, KarinUniversity of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,CARe - Centrum för antibiotikaresistensforskning,Institute of Medicine, School of Public Health and Community Medicine,Centre for antibiotic resistance research, CARe,Sahlgrenska Academy,Univ Gothenburg, Sweden; Primary Hlth Care, Sweden; Univ Gothenburg, Sweden (författare)
  • Stahlgren, G. S.Public Health Agency of Sweden (författare)
  • Sundvall, Pär-DanielUniversity of Gothenburg,Gothenburg University,Göteborgs universitet,CARe - Centrum för antibiotikaresistensforskning,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Centre for antibiotic resistance research, CARe,Institute of Medicine, School of Public Health and Community Medicine,Sahlgrenska Academy,Univ Gothenburg, Sweden; Primary Hlth Care, Sweden; Univ Gothenburg, Sweden(Swepub:gu)xsupar (författare)
  • Hedin, KatarinaLinköpings universitet,Linköping University,Lund University,Lunds universitet,Allmänmedicin och samhällsmedicin,Forskargrupper vid Lunds universitet,Family Medicine and Community Medicine,Lund University Research Groups,Region Jönköping County,Avdelningen för prevention, rehabilitering och nära vård,Medicinska fakulteten,Futurum, Reg Jonkoping Cty, Sweden; Lund Univ, Sweden(Swepub:liu)kathe53 (författare)
  • Linköping UniversityInstitutionen för hälsa, medicin och vård (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:BMC Infectious Diseases: Springer Science and Business Media LLC22:11471-2334

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy